| [1] |
Hammond ME, Hayes DF, Dowsett M,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol,2010,28(16):2784-2795.
|
| [2] |
McGuire W, Carbone PP, Sears ME, et al. Estrogen receptors in human breast cancer[J]/ /McGuire WL, Carbone PP,Vollmer EP. Estrogen receptors in human breast cancer. New York: Raven Press,1975:1-7.
|
| [3] |
Cowen PN, Teasdale J, Jackson P, et al. Oestrogen receptor in breast cancer: Prognostic studies using a new immunohistochemical assay[J].Histopathology,1990,17(4):319-325.
|
| [4] |
Badve SS, Baehner FL, Gray RP, et al. Estrogen and progesterone receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory[J]. J Clin Oncol,2008,26(15):2473-2481.
|
| [5] |
Osborne CK, Yochmowitz MG, Knight WA 3rd, et al. The value of estrogen and progesterone receptors in the treatment of breast cancer[J]. Cancer,1980,46(12):2884-2888.
|
| [6] |
Knight WA 3rd, Osborne CK, McGuire WL. Hormone receptors in primary and advanced breast cancer[J]. Clin Endocrinol Metab,1980,9(2):361-368.
|
| [7] |
Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer[J]. J Clin Oncol,1999,17(5):1474-1481.
|
| [8] |
Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study[J]. Mod Pathol,2004,17(5):1545-1554.
|
| [9] |
Stendahl M, Ryden L, Nordenskjold B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients[J]. Clin Cancer Res,2006,12(15):4614-4618.
|
| [10] |
Yamashita H, Yando Y, Nishio M, et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer[J]. Breast Cancer,2006,13(1):74-83.
|
| [11] |
Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal darcinoma-insitu: ten-year results of European Organisation for Research and Treatment of Cancer Randomized Phase Trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group[J]. J Clin Oncol,2006,24(21):3381-3387.
|
| [12] |
Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? [J]. Ann Oncol,2009,20(9):1499-1504.
|
| [13] |
Mustafa K, Edi B, Andrew D,et al. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? [J]. Curr Oncol Rep,2011,13(1):17-25.
|
| [14] |
Amir E, Miller N, Geddie W,et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer[J].J Clin Oncol,2011,30(6):587-592.
|
| [15] |
Curigliano G, Bagnardi V, Viale G,et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? [J]. Ann Oncol,2011,22(10):2227-2233.
|